Shiva Pharmachem files DRHP for its Rs. 900 crore IPO
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Need to harmonize traditional and modern medicine to combat alarming health problems
CiplaMed 2.0 leverages advanced analytics and automation
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated